-+ 0.00%
-+ 0.00%
-+ 0.00%

Is AbbVie (ABBV) Undervalued On Its Humira Transition And Board Change?

Simply Wall St·11/16/2026 18:18:34
Listen to the news

Board change and new partnerships put AbbVie in focus

AbbVie (ABBV) moved into the spotlight after director Jennifer L. Davis resigned from its board following her appointment as Align Technology’s CEO, while separate collaboration updates reaffirmed AbbVie’s role in outsourced drug discovery.

AbbVie’s share price has climbed to US$295.03, with a 90-day share price return of 13.95% and a 28.66% year to date gain. A 5-year total shareholder return of 204.68% signals strong long run momentum despite recent ETF selling and mixed fund flows.

Spot 35 high quality undervalued stocks that, like AbbVie, pair scaled drug portfolios with current prices that still sit below independently assessed intrinsic value.

AbbVie has just surged toward analysts’ average targets, yet the DCF still points to a sizeable gap to estimated intrinsic value. Do you lean into the momentum today, or wait and hope for a cheaper swing later?

Most Popular Narrative: 4.8% Undervalued

AbbVie last closed at $295.03, compared with a narrative fair value of $310. The gap is modest, but it frames a story built around a completed product handover and a concentrated immunology engine.

According to IamPotato, an investor in the Simply Wall St Community who wrote the narrative, AbbVie’s transition away from Humira is already reshaping how investors should read that valuation gap and the growth profile behind it.

AbbVie has largely completed one of the most closely watched product transitions in pharmaceuticals. Skyrizi and Rinvoq have more than offset the steep decline in Humira, driving double-digit revenue growth and allowing the company to raise full-year guidance. The near-term picture is strong, but the portfolio is now heavily concentrated on these two immunology assets, and longer-term patent and competitive risks remain.

See why 7 investors see AbbVie as 5% undervalued.

The narrative leans on hard recent numbers. AbbVie generated $66.0b in annual revenue and $10.3b in net income, and the writer highlights immunology and neuroscience as the main engines that support that $310 fair value estimate.

At the same time, the view is not one sided. Concentration in Skyrizi and Rinvoq, ongoing pricing and policy risk, high debt levels and negative equity all feature as anchors that could matter more over time than the current valuation discount suggests.

That tension is mirrored in Simply Wall St’s own models. AbbVie trades at a 30.3% discount to an independently assessed future cash flow value of $423.30, yet carries a value score of just 2, a P/E of 50.6x and a dividend yield of 2.47% that is not well covered by earnings.

For investors, the key question is whether the $310 narrative fair value and the deeper DCF gap outweigh concerns around leverage, one off items in recent results and the reliance on a handful of very large therapies.

Result: Fair Value of $310 (UNDERVALUED)

Still, AbbVie’s heavy reliance on Skyrizi and Rinvoq, together with high leverage and negative equity, could change this underpriced story if sentiment turns quickly.

Find out about the key risks to this AbbVie narrative.

Another View: AbbVie looks expensive on earnings multiples

AbbVie may screen as undervalued on future cash flows, but the P/E ratio tells a different story. The stock trades on 50.6x earnings, compared with 16.9x for the US Biotechs industry, a peer average of 47.2x, and a fair ratio estimate of 47.9x that the market could move toward. That premium suggests less room for error if growth or margins disappoint, so how comfortable are you paying up on this metric?

For investors who prefer to anchor on earnings based yardsticks, See what the numbers say about this price — find out in our valuation breakdown.

NYSE:ABBV P/E Ratio as at Nov 2026
NYSE:ABBV P/E Ratio as at Nov 2026

Next Steps

Mixed signals around AbbVie’s value story can feel exciting and uneasy at the same time. Move quickly, review the data, and consider both sides of the argument by exploring the 3 key rewards and 4 important warning signs.

Looking for more ideas beyond AbbVie?

If you stop at AbbVie, you only see part of the opportunity set. Let the data do the heavy lifting and surface fresh candidates for your watchlist.